IMMUNE NETWORK RESEARCH (VSE:IMM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: pete meyer who wrote (53)	9/7/1997 11:39:00 AM
From: burner	of 134

Pete, I did not see anything re a trading halt. Nice gain on friday on over 100,000 shares. Greenline Brokerage was the buyer. The only thing the company has on the burner right now, to my knowledge, is the next phase of macaque study which is focused on obtaining datafor CTB-1. A pre-clinical trial with six SIV-infected primates is expected to begin this fall. Apparently, there will be collaorative support from researchers at Immpheron, Inc.,Harvard Medical School and the National cancer Institute. Positive results would lead to the first limited clinical trial of CTB-1 on selected individuals with AIDS. I think results of the previous research which showed that CTB-1 can improve immune response and implies that CTB-1 could be used as an adjuvant therapy in HIV infection are supposed to be presented in September at a meeting of Human Virology in Baltimore. Perhaps this has already occurred and stimulated the stock reaction. I sure hope measured success is not too far off for the long suffering shareholders of this company. Dan Byrne

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next